SNAP-8
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
SNAP-8 is marketed as a longer-chain, “more potent” successor to Argireline (acetyl Hexapeptide-3) within the same neuro-relaxer family of topical “Botox-like” cosmetic peptides.
What does it do in my body?
SNAP-8 inhibits SNARE-complex formation, reducing neurotransmitter release and muscle contraction at the neuromuscular junction — the same target family as the other relaxer peptides in this cluster, aimed at softening expression-line formation.
How can it help me?
- Where the science stands: Anecdotal: 0 studies, 0 human trials on the public profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to SNAP-8 was captured in the source profile. As a topical-only ingredient, it carries the family-wide benign safety read — topical delivery, no systemic exposure.
Regulatory status: Sold as a cosmetic-grade topical ingredient — legal OTC, not an FDA-reviewed drug.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
SNAP-8 is a topical-only cosmetic ingredient, typically formulated into serums alongside other neuro-relaxer peptides. No specific concentration figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
SNAP-8 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for SNAP-8 yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Marketed as a longer, “more potent” successor to Argireline. The mechanism is plausible and the marketing story is clean — but the published evidence for this exact peptide doesn’t yet back it up.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Inhibits SNARE-complex formation → reduced neurotransmitter release → reduced muscle contraction |
| Evidence base | Anecdotal: 0 studies, 0 human trials on the public profile |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
SNAP-8 is marketed as a longer-chain, “more potent” successor to Argireline (acetyl Hexapeptide-3) within the same neuro-relaxer family of topical “Botox-like” cosmetic peptides.
How it works
SNAP-8 inhibits SNARE-complex formation, reducing neurotransmitter release and muscle contraction at the neuromuscular junction — the same target family as the other relaxer peptides in this cluster, aimed at softening expression-line formation.
What the research shows
The public profile grade is Anecdotal: 0 studies, 0 human trials. OHM’s internal 0035 categorization pass keeps SNAP-8 at Tier D / provisional (encyclopedia-only), describing the evidence as “cosmetic-marketing-grade evidence only … no meaningful published RCT base”.
Real-world protocol
SNAP-8 is a topical-only cosmetic ingredient, typically formulated into serums alongside other neuro-relaxer peptides. No specific concentration figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to SNAP-8 was captured in the source profile. As a topical-only ingredient, it carries the family-wide benign safety read — topical delivery, no systemic exposure.
Regulatory status
Sold as a cosmetic-grade topical ingredient — legal OTC, not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · Vialox · Syn-Ake · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · Vialox · Syn-Ake · Pentapeptide-18